reaction was disclosed the medical records were examined to see if it had been noted. There are spaces to record "drug allergy" and "contraindicated drugs" on prescription charts and inside the back cover of medical notes at our hospital. These too were examined. Reactions listed in standard texts23 were regarded as likely and others as unlikely. Seventy seven patients reported 97 adverse drug reactions on direct questioning (table) . The current medical history recorded only 53 of these, and the prescription chart only 17 of the 53. None of the reactions was recorded inside the back cover of the clinical notes. Important reactions included facial swelling with penicillins (4), gastrointestinal bleeding with aspirin (3) or other non-steroidal anti-inflammatory drugs (1), and pulmonary embolism with oral contraceptives (1) . The reactions elicited by questionnaire appeared likely in 74 cases, of which 42 were recorded in the current notes, though for likely penicillin reactions 20 out of 28 were recorded. The question "Have you ever needed treatment by a doctor or at a hospital for a reaction to a medicine or tablet?" did not add to information from the other questions.
Comment
The simple questions, Have any medicines or tablets ever disagreed with you or caused an allergy? and Are you able to take aspirin or penicillin? identified 97 reactions. Most (76%) of these were likely to have been related to the drug, so that the questionnaire was reasonably specific for adverse reactions, which are anyway difficult to diagnose.4 Doctors recorded only half of the reactions elicited by the questionnaire, and they did not preferentially record well established reactions.
We have no evidence that any patient came to harm as a result of the imperfect recording of adverse drug reactions, but we believe that knowing a patient's history of such reactions is important to protect both the patient and the doctor. Doctors should be encouraged to ask the simple questions which we used when admitting patients, and to record the data they obtain. A hazard label for the front of the notes and the prescription chart might be helpful. The glutathione S-transferase enzyme GSTM1 has a polymorphic expression, with about half of people from various racial groups lacking enzyme activity.' The enzyme detoxicates several carcinogens including benzo[a]pyrene-4,5 oxide and it has been suggested that smokers who lack glutathione S-transferase activity are at increased risk of developing lung cancer, particularly adenocarcinoma.2 Enzyme deficiency seems to be due to deletion of the coding gene GSTM1, and simple polymerase chain reaction assays to detect this deletion have been developed.3
The main risk factors for transitional cell carcinoma of the bladder are smoking and occupational exposure to carcinogens.4 In view of the reported association between glutathione S-transferase and susceptibility to lung cancer, we examined whether lack of the enzyme was also associated with susceptibility to bladder cancer.
Subjects, methods, and results
We recruited 53 patients with transitional cell carcinoma of the bladder (34 men, 19 women; mean age 75) and 52 control patients (45 men, seven women; mean age 70) from Freeman Hospital Urology Department, Newcastle upon Tyne. The control patients were either having transurethral resection of the prostate for bladder outflow obstruction or were receiving treatment for stones, stress incontinence, unstable bladder, or neuropathic bladder, and all had had cystoscopy to exclude a bladder tumour. We also recruited 58 healthy volunteers from staff and students of Newcastle University (24 men, 34 women). The study was approved by the local ethics committee, and patients and volunteers gave informed consent.
We detected deletion of GSTM1 in leucocyte DNA by a polymerase chain reaction assay using the primers GCTTCACGTGTTATGGAGGTTC(fromintron6of GSTM1)andGAGATGAAGTCCTTCAGATTT(from exon 7), which gave rise to a 160 base pair product in subjects who were heterozygous or homozygous wild type (GSTM1 positive).' As a control, we also ran an assay for the non-polymorphic gene GSTM2 (for muscle specific glutathione S-transferase) in parallel using as primers CCAGAATACCTGCAGGCACTC (exon 6) and GTATGACAAATCTGTGGTGTCC (intron 6). Conditions for both assays were 40 cycles of 1 min at 95°C, 1 5 min at 47°C, and 2 min at 70°C. All assays were repeated at least twice.
The After a road test in a dual controlled, automatic vehicle on a set route around public roads subjects were graded by the instructor into pass or fail groups. Subjects were then randomly allocated into two groups, one of which (n -27) was tested on the stroke drivers screening assessment and scores from the three tasks were used to predict the likelihood of passing a road test. The subject's general practitioner was given the results of the cognitive tests with a recommendation about fitness to drive. The control group (n-25) was instructed to request the advice of their general practitioners regarding their fitness to drive. They did not undergo cognitive testing because it might have influenced their request to the general practitioner.
After six months subjects were contacted to ascertain the decisions on fitness to drive. The two types ofassessment, cognitive and standard procedure, were compared to determine which assessment method agreed most closely with the performance on the road test.
There were no significant differences between the groups in age (mean 58&8 years in the assessment group v 60-2 years in the control group), sex (23 men v 23 men) or side of hemiplegia (13 right v 7 right) (p > 0 05). However, those in the cognitive assessment group were seen significantly later after their stroke (mean 44 4 weeks) than controls (mean 23-0 weeks). For each group the decision method was compared with the grading of "on the road" performance (table) . The stroke drivers screening assessment correctly predicted the road performance of 81% of patients, whereas the performance of only 56% was correctly predicted in the control group. The 95% confidence intervals indicate that the assessment predicted road performance significantly better than chance. The decision in the control group was made by either the general practitioner or the Driver and Vehicle Licensing Agency, but this was no better than chance.
By six months 29 patients had resumed driving, 28 of whom had been advised they were fit to drive.
Comment
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